147 related articles for article (PubMed ID: 10801223)
1. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver.
Kanamitsu S; Ito K; Sugiyama Y
Pharm Res; 2000 Mar; 17(3):336-43. PubMed ID: 10801223
[TBL] [Abstract][Full Text] [Related]
2. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.
Komatsu K; Ito K; Nakajima Y; Kanamitsu Si; Imaoka S; Funae Y; Green CE; Tyson CA; Shimada N; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):475-81. PubMed ID: 10725317
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.
Perkins EJ; Posada M; Kellie Turner P; Chappell J; Ng WT; Twelves C
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):355-367. PubMed ID: 29119333
[TBL] [Abstract][Full Text] [Related]
4. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
5. Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.
Wang JS; Wen X; Backman JT; Neuvonen PJ
J Pharmacol Exp Ther; 2002 Jul; 302(1):43-9. PubMed ID: 12065698
[TBL] [Abstract][Full Text] [Related]
6. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
[TBL] [Abstract][Full Text] [Related]
7. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
Madsen H; Enggaard TP; Hansen LL; Klitgaard NA; Brøsen K
Clin Pharmacol Ther; 2001 Jan; 69(1):41-7. PubMed ID: 11180037
[TBL] [Abstract][Full Text] [Related]
9. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.
Tremaine LM; Wilner KD; Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():31-6. PubMed ID: 9068933
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
Miners J
Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
[No Abstract] [Full Text] [Related]
11. Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats.
Fukuno S; Nagai K; Yamamoto K; Tanimura T; Nabe T; Konishi H
Biopharm Drug Dispos; 2019 Jul; 40(7):225-233. PubMed ID: 31215040
[TBL] [Abstract][Full Text] [Related]
12. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo.
Tassaneeyakul W; Birkett DJ; Pass MC; Miners JO
Br J Clin Pharmacol; 1996 Dec; 42(6):774-8. PubMed ID: 8971435
[TBL] [Abstract][Full Text] [Related]
13. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.
Carlile DJ; Hakooz N; Bayliss MK; Houston JB
Br J Clin Pharmacol; 1999 Jun; 47(6):625-35. PubMed ID: 10383540
[TBL] [Abstract][Full Text] [Related]
14. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica.
Ishihara K; Kushida H; Yuzurihara M; Wakui Y; Yanagisawa T; Kamei H; Ohmori S; Kitada M
J Pharm Pharmacol; 2000 Aug; 52(8):1023-9. PubMed ID: 11007075
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibitory effects of phenytoin, diclofenac, phenylbutazone and a series of sulfonamides on hepatic cytochrome P4502C activity in vitro, and correlation with some molecular descriptors in the dwarf goat (Caprus hircus aegagrus).
Zweers-Zeilmaker WM; Horbach GJ; Witkamp RF
Xenobiotica; 1997 Aug; 27(8):769-80. PubMed ID: 9293615
[TBL] [Abstract][Full Text] [Related]
16. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
18. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
[TBL] [Abstract][Full Text] [Related]
19. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
20. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
Tang C; Shou M; Rodrigues AD
Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
